Hugel Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Hugel wird ein jährliches Gewinn- und Umsatzwachstum von 18.5% bzw. 14.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.8% betragen.

Wichtige Informationen

18.5%

Wachstumsrate der Gewinne

17.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	51.0%
Wachstumsrate der Einnahmen	12.7%
Zukünftige Eigenkapitalrendite	14.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

Mar 19

What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

Feb 25

Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

Feb 04

The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Jan 17

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 29

Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

Dec 14

How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Nov 24

Gewinn- und Umsatzwachstumsprognosen

KOSDAQ:A145020 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (KRW Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	488,422	157,650	113,333	165,420	7
12/31/2025	433,349	133,483	98,200	142,543	9
12/31/2024	369,094	101,650	76,667	132,286	6
3/31/2024	329,626	97,506	122,106	136,897	N/A
12/31/2023	319,700	93,076	102,056	117,705	N/A
9/30/2023	316,245	78,490	109,406	120,833	N/A
6/30/2023	302,105	66,435	66,764	101,587	N/A
3/31/2023	284,412	59,834	35,753	73,440	N/A
12/31/2022	281,675	60,558	41,339	80,626	N/A
9/30/2022	253,838	62,665	28,379	67,832	N/A
6/30/2022	235,499	55,511	22,741	76,750	N/A
3/31/2022	229,679	54,981	48,052	96,503	N/A
12/31/2021	231,859	56,506	37,538	85,940	N/A
9/30/2021	241,634	64,582	53,040	108,436	N/A
6/30/2021	243,369	54,222	53,937	98,028	N/A
3/31/2021	233,604	54,615	44,381	86,717	N/A
12/31/2020	211,038	41,992	29,134	74,302	N/A
9/30/2020	197,629	39,728	15,363	53,179	N/A
6/30/2020	194,699	39,910	28,249	62,820	N/A
3/31/2020	196,707	36,815	17,484	53,861	N/A
12/31/2019	204,568	44,612	48,614	76,995	N/A
9/30/2019	209,360	47,993	45,825	73,461	N/A
6/30/2019	193,154	60,763	47,979	70,709	N/A
3/31/2019	185,732	64,104	55,724	73,726	N/A
12/31/2018	182,392	69,736	49,160	65,796	N/A
9/30/2018	173,688	75,552	54,338	63,870	N/A
6/30/2018	180,322	69,985	48,665	57,628	N/A
3/31/2018	183,613	73,918	49,273	56,256	N/A
12/31/2017	182,085	72,827	N/A	64,192	N/A
9/30/2017	169,778	67,665	N/A	66,221	N/A
6/30/2017	161,011	63,022	N/A	68,481	N/A
3/31/2017	145,786	56,096	N/A	63,915	N/A
12/31/2016	124,189	43,273	N/A	45,141	N/A
9/30/2016	108,883	36,540	N/A	37,526	N/A
6/30/2016	94,231	73,093	N/A	29,734	N/A
3/31/2016	80,098	39,216	N/A	24,385	N/A
12/31/2015	65,066	33,929	N/A	19,764	N/A
9/30/2015	59,328	33,924	N/A	9,518	N/A
6/30/2015	49,887	-12,904	N/A	7,431	N/A
12/31/2014	40,350	13,150	N/A	10,568	N/A
12/31/2013	29,170	7,307	N/A	6,876	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A145020Das prognostizierte Gewinnwachstum (18.5% pro Jahr) liegt über der Sparquote (2.5%).

Ertrag vs. Markt: A145020Die Erträge des Unternehmens (18.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (28.3% pro Jahr).

Hohe Wachstumserträge: A145020Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: A145020Die Einnahmen des Unternehmens (14.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt KR (10.2% pro Jahr).

Hohe Wachstumseinnahmen: A145020Die Einnahmen des Unternehmens (14.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: A145020Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.8 %).

Hugel Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 13% to ₩254,889

Price target increased by 8.7% to ₩201,750

Consensus EPS estimates increase by 38%

Price target increased by 8.1% to ₩172,571

Price target decreased by 8.8% to ₩159,250

Price target increased by 7.3% to ₩189,714

Recent updates

Price target increased by 13% to ₩254,889

Investor sentiment improves as stock rises 21%

Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)

Now 21% undervalued

Now 22% undervalued

Hugel, Inc. to Report Q1, 2024 Final Results on May 09, 2024

Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Now 23% undervalued

Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings

Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)

Investor sentiment improves as stock rises 19%

Price target increased by 8.7% to ₩201,750

Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Consensus EPS estimates increase by 38%

Price target increased by 8.1% to ₩172,571

Hugel Resubmits BLA for Its Botulinum Toxin, Letybo to the U.S. Fda

Price target decreased by 8.8% to ₩159,250

Hugel, Inc. (KOSDAQ:A145020) acquired additional 3.13% stake in Across Co., Ltd for KRW 9.385 billion.

Investor sentiment deteriorates as stock falls 18%

Price target increased by 7.3% to ₩189,714

Investor sentiment deteriorates as stock falls 18%

Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Now 29% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia

Less than half of directors are independent

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,875

Hugel, Inc. Appoints Brent Saunders to its Board of Director

No independent directors

Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Price target decreased to ₩214,889

Investor sentiment deteriorated over the past week

Price target decreased to ₩238,333

Consensus EPS estimates fall by 10%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

New 90-day low: ₩174,400

Hugel, Inc. Announces Approval to Launch of Letybo 50U in Prc Market

Hugel, Inc., Annual General Meeting, Mar 26, 2021

Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

Hugel, Inc. to Report Fiscal Year 2020 Results on Feb 09, 2021

Investor sentiment improved over the past week

New 90-day high: ₩224,700

The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Price target raised to ₩251,818

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

New 90-day low: ₩175,600

How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Price target raised to ₩241,515

Price target raised to ₩227,788

Price target raised to ₩211,861

Market bids up stock over the past week

New 90-day high: ₩219,900

New 90-day high - ₩194,600

Hugel, Inc. to Report First Half, 2020 Results on Aug 11, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken